Therapeutic Advances in Urology (Nov 2023)

CO laser therapy for management of stress urinary incontinence in women: a systematic review and meta-analysis

  • Bandr Hafidh,
  • Saeed Baradwan,
  • Hassan M. Latifah,
  • Abdulrahim Gari,
  • Hussein Sabban,
  • Hanin Hassan Abduljabbar,
  • Afaf Tawfiq,
  • Ghaidaa Farouk Hakeem,
  • Alya Alkaff,
  • Nabigah Alzawawi,
  • Radiah Iskandarani,
  • Kausar Khurshid,
  • Kausar Aisha Syed,
  • Ammar Y. Alkhiary,
  • Ibtihal Abdulaziz Bukhari,
  • Maha Al Baalharith,
  • Ahmed Abu-Zaid

DOI
https://doi.org/10.1177/17562872231210216
Journal volume & issue
Vol. 15

Abstract

Read online

Background: Carbon dioxide (CO 2 ) laser therapy is an emerging treatment for women with stress urinary incontinence (SUI). Objectives: To examine the efficacy of CO 2 laser therapy for management of SUI-related symptoms in women. Design: A systematic review and meta-analysis of randomized controlled trials and cohort studies. Data sources and methods: Four databases were screened until January 2023. All efficacy continuous endpoints were assessed via subtraction of the posttreatment from pretreatment values. The data were summarized as mean difference (MD) with 95% confidence interval (CI) using the random-effects model. Results: A total of 15 studies with 700 patients were analyzed. CO 2 laser therapy significantly decreased the 1-h pad weights at 3 months [ n = 5 studies, MD = −3.656 g, 95% CI (−5.198, −2.113), p < 0.001], 6 months [ n = 6 studies, MD = −6.583 g, 95% CI (−11.158, −2.008), p = 0.005], and 12 months [ n = 6 studies, MD = −3.726 g, 95% CI (−6.347, −1.106), p = 0.005]. Moreover, CO 2 laser therapy significantly decreased the International Consultation of Incontinence Questionnaire-Urinary Incontinence Short Form Scores at 3 months [ n = 10 studies, MD = −4.805, 95% CI (−5.985, −3.626), p < 0.001] and 12-months [ n = 6 studies, MD = −3.726, 95% CI (−6.347, −1.106), p = 0.005]. Additionally, CO 2 laser therapy significantly decreased the Pelvic Floor Impact Questionnaire scores at 6 months [ n = 2 studies, MD = −11.268, 95% CI (−18.671, −3.865), p = 0.002] and 12 months [ n = 2 studies, MD = −10.624, 95% CI (−18.145, −3.103), p = 0.006]. Besides, CO 2 laser therapy significantly decreased the Urogenital Distress Inventory-6 scores at 3 months [ n = 2 studies, MD = −21.997, 95% CI (−32.294, −11.699), p < 0.001], but not at 6 months [ n = 3 studies, MD = −3.034, 95% CI (−7.357, 1.259), p = 0.169]. Lastly, CO 2 laser therapy significantly increased the Vaginal Health Index Score at 6 months [ n = 2 studies, MD = 2.826, 95% CI (0.013, 5.638), p = 0.047] and 12 months [MD = 1.553, 95% CI (0.173, 2.934), p = 0.027]. Conclusion: CO 2 laser therapy improved the SUI-related symptoms in women. To obtain solid conclusions, future studies should be well-designed with standardized settings, consistent therapeutic protocols, and long-term follow-up periods.